Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaf034
Abstract: Abstract Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up… read more here.
Keywords: early access; access program; rezafungin; program ... See more keywords
A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13286
Abstract: Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of… read more here.
Keywords: safety tolerability; rezafungin; randomized double; double blind ... See more keywords
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
Sign Up to like & getrecommendations! Published in 2021 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00842-21
Abstract: Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species of Candida and Aspergillus, including subsets of resistant strains, and Pneumocystis jirovecii. The objective of this analysis was to develop… read more here.
Keywords: pharmacokinetics rezafungin; population; population pharmacokinetics; rezafungin ... See more keywords
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01572-18
Abstract: Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida auris strains, using the neutropenic mouse invasive candidiasis model. ABSTRACT Rezafungin (CD101)… read more here.
Keywords: invasive candidiasis; rezafungin; mouse invasive; candida auris ... See more keywords
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
Sign Up to like & getrecommendations! Published in 2024 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01584-23
Abstract: ABSTRACT Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the… read more here.
Keywords: restore; treatment; caspofungin; candidemia ... See more keywords
In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Fungi"
DOI: 10.3390/jof10060397
Abstract: The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin. Using the broth microdilution (BMD) method, the… read more here.
Keywords: caspofungin; rezafungin; anidulafungin caspofungin; invasive fungal ... See more keywords